A carregar...
Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
The introduction of biologics for the treatment of patients with refractory asthma represented a marked therapeutic advance. For more than 10 y, the only biologic available has been the monoclonal anti-IgE antibody omalizumab, reserved for patients with asthma caused by perennial allergen. In recent...
Na minha lista:
| Publicado no: | Hum Vaccin Immunother |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7644228/ https://ncbi.nlm.nih.gov/pubmed/32401603 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2020.1753440 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|